A technical overview of how in vitro discovery platforms support VHH antibody and peptide discovery across challenging protein classes, from soluble enzymes to membrane proteins, toxic antigens and complex multimeric targets, using tailored antigen presentation strategies. Read more

VHH antibodies provide modular, high-performance components that can enhance biologics across multiple modalities. From albumin-binding half-life extension to bi-/multi-specific engineering and intracellular TPD, VHH bolt-ons enable more flexible, efficient and targeted therapeutic design. This article examines the key applications, design considerations e case studies that illustrate how VHH domains support next-generation engineered biologics. Read more

Choosing the right display technology is a critical decision in therapeutic and diagnostic discovery procedures. This article compares CIS Display™ with Phage Display, focusing on their underlying techniques, important benefits, and suitable applications. Read more

Next-generation sequencing is redefining antibody discovery. From validating library diversity to uncovering rare binders and powering AI-driven design, NGS offers additional insights that enhance VHH antibody discovery and selection. Read more

Today, the term ‘undruggable’ is being redefined. Advances in membrane protein solubilization, allosteric modulation, and therapeutic viral vectors have led to proof that these targets can be tackled. Read more

Traditionally, antibody generation relied on immunizing animals (e.g. mice, rabbits, or even llamas) to raise binders against a target antigen. However, emerging synthetic antibody library technologies now allow scientists to bypass animal immunization by using in silico designed vast libraries of human or humanized antibody fragments.